Vanda Pharmaceuticals Inc (VNDA) reports strong Fanapt sales growth and strategic initiatives, despite facing increased ...
Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...
H.C. Wainwright raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $20 from $18 and keeps a Buy rating on the shares. The firm ...
Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) had its price target upped by HC Wainwright from $18.00 to $20.00 in a research note issued to investors on Tuesday morning,Benzinga reports. HC ...
Kevin Moran; Chief Financial Officer, Senior Vice President, Treasurer; Vanda Pharmaceuticals Inc Mihael Polymeropoulos; Chairman of the Board, President, Chief Executive Officer; Vanda ...
In the assessment of 12-month price targets, analysts unveil insights for Vanda Pharma, presenting an average target of $18.4 ...
Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.
Hello, and thank you for standing by. At this time, I would like to welcome you to the Q4 2024 Vanda Pharmaceuticals, Inc. Earnings Conference Call. [Operator Instructions] I would now like to ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company focused on developing and commercializing therapies for unmet medical needs, has been navigating a complex landscape of ...
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total ...
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Vanda (VNDA – Research Report) on February 14 and set a price target of ...